Oscar Health (OSCR) is back in focus after reporting record first quarter 2026 earnings, with net income of US$679 million and diluted EPS of US$2.07, while management reaffirmed full year guidance.

The stock has reacted strongly to the record Q1 result, with a 30 day share price return of 47.47% and a 90 day gain of 65.45%. The 3 year total shareholder return of 196.80% contrasts with a weaker 5 year record, suggesting momentum is currently building from a lower base.

If Oscar Health’s move has you rethinking where growth could come from in healthcare, it may be worth scanning for other tech driven insurers and platforms via our 34 healthcare AI stocks

With earnings beating analyst EPS forecasts and the share price already up sharply over 1 year and 3 years, the key question now is whether Oscar Health still trades below its fundamentals or if the market is already pricing in future growth.

Most Popular Narrative: 38.4% Overvalued

Oscar Health’s most followed narrative pegs fair value at $15.40, which sits well below the last close at $21.31, so the story leans heavily on future earnings power and margin repair to justify that earlier target.

The analysts have a consensus price target of $15.4 for Oscar Health based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $23.0, and the most bearish reporting a price target of just $10.0.

Want to see what has to happen for those earnings to line up with that fair value? The narrative leans on rapid top line growth, rising margins and a stronger return profile. Curious how those moving parts are stitched together into one valuation story?

Result: Fair Value of $15.40 (OVERVALUED)

However, the fair value story could shift quickly if the House Judiciary subpoenas uncover issues, or if changing ACA subsidies alter Oscar Health’s addressable market.

Another Angle: Market Pricing Versus Business Scale

That 38.4% “overvalued” label from the narrative sits uncomfortably next to how the market is actually pricing Oscar Health’s current scale. On about $13.3b of revenue, the stock trades on a P/S of roughly 0.5x, compared with 0.7x for similar peers and 1.1x for the wider US Insurance group. The estimated fair ratio is also 0.7x, so today’s multiple sits well below where the market could move if sentiment improves, but the analyst target is already under the current $21.31 share price. This leaves you to weigh up whether that discount in the multiple reflects a margin of safety or a warning flag.

To pressure test this view against the earnings based fair value story, it is worth checking how the valuation stacks up in a fuller multiples breakdown, including the gap between today’s P/S, peers and the fair ratio, and what that might mean for future upside or downside risk for your own thesis, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With the story pulling in different directions, are you leaning toward the opportunity side or the risk side of Oscar Health’s setup, and how quickly do you want to firm up your own view by weighing the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Oscar Health has sharpened your focus, do not stop here. Fresh stock ideas can help you build a more resilient and opportunity rich portfolio.

• Spot potential bargains quickly by scanning companies that combine quality fundamentals with attractive pricing using our 49 high quality undervalued stocks.
• Strengthen the defensive side of your portfolio by checking out companies with lower risk profiles through the 71 resilient stocks with low risk scores.
• Stay ahead of the crowd by reviewing companies with strong fundamentals that are still off most radars via our screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.